New drug combo aims to control Tough-to-Treat leukemia
NCT ID NCT03147612
Summary
This study is testing a multi-step treatment plan for adults with a specific type of acute lymphoblastic leukemia (ALL) that is linked to a genetic change called the Philadelphia chromosome. The plan combines lower-intensity chemotherapy with two targeted drugs, ponatinib and blinatumomab, to try to get the cancer into remission and keep it under control. The goal is to see if this approach is effective and safe for patients with newly diagnosed or hard-to-treat disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.